

**Company registration number: 281800**

**RINGSEND & DISTRICT RESPONSE TO DRUGS CLG  
(COMPANY LIMITED BY GUARANTEE)**

**FINANCIAL STATEMENTS**

**FOR THE YEAR ENDED 31ST DECEMBER 2023**

**RINGSEND & DISTRICT RESPONSE TO DRUGS CLG  
(COMPANY LIMITED BY GUARANTEE)**

**Company Information**

<b>Directors</b>	Elizabeth Bissett Thomas Crilly Anthony Kelly (Resigned 3rd March 2023) Teresa Weafer Jeff Greene (Appointed 29th September 2023)
<b>Secretary</b>	Joseph Grennell
<b>Company number</b>	281800
<b>Registered office</b>	17 Irishtown Road Irishtown, Dublin 4.
<b>Business address</b>	17 Irishtown Road, Irishtown Dublin 4.
<b>Auditor</b>	Hayden Brown Grafton Buildings 34 Grafton Street Dublin 2
<b>Bankers</b>	Bank of Ireland, College Green, Dublin 2.

**RINGSEND & DISTRICT RESPONSE TO DRUGS CLG  
(COMPANY LIMITED BY GUARANTEE)**

**Contents**

	<b>Page</b>
Directors report	<b>1 - 2</b>
Directors responsibilities statement	<b>3</b>
Independent auditor's report to the members	<b>4 - 6</b>
Income and expenditure account	<b>7</b>
Balance sheet	<b>8</b>
Statement of changes in reserves	<b>9</b>
Statement of cash flows	<b>10</b>
Notes to the financial statements	<b>11 - 20</b>

**RINGSEND & DISTRICT RESPONSE TO DRUGS CLG  
(COMPANY LIMITED BY GUARANTEE)**

**DIRECTORS REPORT  
YEAR ENDED 31ST DECEMBER 2023**

The directors present their report and the financial statements of the company for the year ended 31st December 2023.

**Directors**

The names of the persons who at any time during the financial year were directors of the company are as follows:

Elizabeth Bissett  
Thomas Crilly  
Anthony Kelly (Resigned 3rd March 2023)  
Teresa Weafer  
Jeff Greene (Appointed 29th September 2023)

**Principal activities**

The principle activity of the company is to provide a safe, supportive and holistic environment which encourages a drug free recovery for young people and their families, through the provision of training, support and aftercare for the people of Ringsend and surrounding district. The company achieved charitable status from the Revenue Commissioners in June 2003.

**Principal risks and uncertainties**

The principle risk and uncertainty affecting Ringsend & District Response to Drugs CLG for the year ahead is the reduction in funding from government grants which the company receives and the effects this will have on the ongoing operations of the organisation. The directors have instituted measures to ensure that costs are reduced in line with future funding streams.

**Going Concern**

The company is dependent on income provided from government funders. As with many government funded organisations, the company is affected by both budgetary constraints implemented by the national government and external economic restraints. The directors have reviewed all relevant information and are confident that the company has adequate financial resources to continue in operational existence for the foreseeable future. Consequently, the directors consider it appropriate to prepare the financial statements on a going concern basis.

**Taxation Status**

The company, as a charity (CHY no. 14910), is not liable to corporation tax under section 207 (as applied to companies by section 76) of the Taxes Consolidation Act, 1997. The company is registered with the Charities Regulatory Authority under section 39 of the Charities Act 2009 (reference number 20049928)

**Accounting records**

The measures taken by the directors to secure compliance with the requirements of sections 281 to 285 of the Companies Act 2014 with regard to the keeping of accounting records are the implementation of necessary policies and procedures for recording transactions, the employment of competent accounting personnel with appropriate expertise and the provision of adequate resources to the financial function. The accounting records of the company are located at 17 Irishtown Road, Irishtown, Dublin 4.

**RINGSEND & DISTRICT RESPONSE TO DRUGS CLG  
(COMPANY LIMITED BY GUARANTEE)**

**DIRECTORS REPORT (CONTINUED)  
YEAR ENDED 31ST DECEMBER 2023**

**Relevant audit information**

In the case of each of the persons who are directors at the time this report is approved in accordance with section 332 of Companies Act 2014:

- so far as each director is aware, there is no relevant audit information of which the company's statutory auditors are unaware, and
- each director has taken all the steps that he or she ought to have taken as a director in order to make himself or herself aware of any relevant audit information and to establish that the company's statutory auditors are aware of that information.

**Auditors**

The auditors, Hayden Brown, have indicated their willingness to continue in office in accordance with the provisions of Section 383(2) of the Companies Act 2014.

This report was approved by the board of directors on 8th May 2024 and signed on behalf of the board by:

Elizabeth Bissett  
Director

*Elizabeth Bissett*

Thomas Crilly  
Director

*Thomas F. Crilly*

**RINGSEND & DISTRICT RESPONSE TO DRUGS CLG  
(COMPANY LIMITED BY GUARANTEE)**

**DIRECTORS RESPONSIBILITIES STATEMENT  
YEAR ENDED 31ST DECEMBER 2023**

The directors are responsible for preparing the directors report and the financial statements in accordance with applicable Irish law and regulations.

Irish company law requires the directors to prepare financial statements for each financial year. Under the law, the directors have elected to prepare the financial statements in accordance with Companies Act 2014 and FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" issued by the Financial Reporting Council, and promulgated by the Institute of Chartered Accountants in Ireland. Under company law, the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the assets, liabilities and financial position of the company as at the financial year end date and of the surplus or deficit of the company for the financial year and otherwise comply with the Companies Act 2014.

In preparing these financial statements, the directors are required to:

- select suitable accounting policies and then apply them consistently;
- make judgments and accounting estimates that are reasonable and prudent;
- state whether the financial statements have been prepared in accordance with applicable accounting standards, identify those standards, and note the effect and the reasons for any material departure from those standards; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The directors confirm that they have complied with the above requirements in preparing the financial statements.

The directors are responsible for ensuring that the company keeps or causes to be kept adequate accounting records which correctly explain and record the transactions of the company, enable at any time the assets, liabilities, financial position and surplus or deficit of the company to be determined with reasonable accuracy, enable them to ensure that the financial statements and directors report comply with the Companies Act 2014 and enable the financial statements to be audited. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

This statement was approved by the board of directors on 8th May 2024 and signed on behalf of the board

Elizabeth Bissett  
Director



Thomas Crilly  
Director



**RINGSEND & DISTRICT RESPONSE TO DRUGS CLG  
(COMPANY LIMITED BY GUARANTEE)**

**INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF  
RINGSEND & DISTRICT RESPONSE TO DRUGS CLG (CONTINUED)  
YEAR ENDED 31ST DECEMBER 2023**

**Report on the audit of the financial statements**

***Opinion***

We have audited the financial statements of Ringsend & District Response to Drugs CLG for the year ended 31st December 2023 which comprise the Income and Expenditure Account, balance sheet, statement of changes in reserves, statement of cashflows and notes to the financial statements, including a summary of significant accounting policies set out in note 2. The financial reporting framework that has been applied in their preparation is Irish law and FRS 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland.

In our opinion the financial statements:

- give a true and fair view of the assets, liabilities and financial position of the company as at 31st December 2023 and of its surplus for the year then ended;
- have been properly prepared in accordance with FRS 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland; and
- have been prepared in accordance with the requirements of the Companies Act 2014.

***Basis for opinion***

We conducted our audit in accordance with International Standards on Auditing (Ireland) (ISAs (Ireland)) and applicable law. Our responsibilities under those standards are further described in the section of our report. We are independent of the company in accordance with the ethical requirements that are relevant to our audit of the financial statements in Ireland, including the Ethical Standard issued by the Irish Auditing and Accounting Supervisory Authority (IAASA), and the provisions available for small entities, in the circumstances set out in note 15 to the financial statements, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

***Conclusions relating to going concern***

In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the Company's ability to continue as a going concern for a period of at least twelve months from the date when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report.

**RINGSEND & DISTRICT RESPONSE TO DRUGS CLG  
(COMPANY LIMITED BY GUARANTEE)**

**INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF  
RINGSEND & DISTRICT RESPONSE TO DRUGS CLG (CONTINUED)  
YEAR ENDED 31ST DECEMBER 2023**

***Other Information***

The directors are responsible for the other information. The other information comprises the information included in the annual report, other than the financial statements and our auditor's report thereon. Our opinion on the financial statements does not cover the other information and except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

***Opinions on other matters prescribed by the Companies Act 2014***

Based solely on the work undertaken in the course of the audit, we report that:

- in our opinion, the information given in the directors report is consistent with the financial statements; and
- in our opinion, the directors report has been prepared in accordance with applicable legal requirements.

We have obtained all the information and explanations which we consider necessary for the purposes of our audit.

In our opinion the accounting records of the company were sufficient to permit the financial statements to be readily and properly audited, and financial statements are in agreement with the accounting records.

***Matters on which we are required to report by exception***

Based on the knowledge and understanding of the company and its environment obtained in the course of the audit, we have not identified material misstatements in the directors report.

The Companies Act 2014 requires us to report to you if, in our opinion, the disclosures of directors' remuneration and transactions required by sections 305 to 312 of the Act are not made. We have nothing to report in this regard.

***Respective responsibilities***

***Responsibilities of directors for the financial statements***

As explained more fully in the directors responsibilities statement, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the directors determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the directors are responsible for assessing the company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the management either intends to liquidate the company or to cease operations, or have no realistic alternative but to do so.



**RINGSEND & DISTRICT RESPONSE TO DRUGS CLG  
(COMPANY LIMITED BY GUARANTEE)**

**INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF  
RINGSEND & DISTRICT RESPONSE TO DRUGS CLG (CONTINUED)  
YEAR ENDED 31ST DECEMBER 2023**

***Auditor's responsibilities for the audit of the financial statements***

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (Ireland) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with ISAs (Ireland), we exercise professional judgment and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the directors.
- Conclude on the appropriateness of the directors use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

***The purpose of our audit work and to whom we owe our responsibilities***

Our report is made solely to the company's members, as a body, in accordance with section 391 of the Companies Act 2014. Our audit work has been undertaken so that we might state to the company's members those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company's members, as a body, for our audit work, for this report, or for the opinions we have formed.

  
Ciarán Murray

For and on behalf of  
Hayden Brown  
Chartered Accountants and Statutory Audit Firm  
Grafton Buildings  
34 Grafton Street  
Dublin 2  
8th May 2024

**RINGSEND & DISTRICT RESPONSE TO DRUGS CLG  
(COMPANY LIMITED BY GUARANTEE)**

**INCOME AND EXPENDITURE ACCOUNT  
YEAR ENDED 31ST DECEMBER 2023**

	Note	2023 €	2022 €
Income		1,148,855	1,133,292
Gross income		<u>1,148,855</u>	<u>1,133,292</u>
Administrative expenses		(1,141,155)	(1,115,159)
Surplus for the financial year	6	<u>7,700</u>	<u>18,133</u>

All the activities of the company are from continuing operations.

The company has no other recognised items of income and expenses other than the results for the year as set out above.

The financial statements were approved by the board of directors on 8th May 2024 and signed on behalf of the board by:

Elizabeth Bissett  
Director

*Elizabeth Bissett*

Thomas Crilly  
Director

*Thomas F. Crilly*

The notes on pages 11 to 20 form part of these financial statements.

**RINGSEND & DISTRICT RESPONSE TO DRUGS CLG  
(COMPANY LIMITED BY GUARANTEE)**

**BALANCE SHEET  
31ST DECEMBER 2023**

		2023		2022	
	Note	€	€	€	€
<b>Fixed assets</b>					
Tangible assets	8	433,299		448,784	
			433,299		448,784
<b>Current assets</b>					
Debtors	9	39,728		27,687	
Cash at bank and in hand		193,188		190,153	
		232,916		217,840	
<b>Creditors: amounts falling due within one year</b>	10	(151,975)		(143,499)	
<b>Net current assets</b>			80,941		74,341
<b>Total assets less current liabilities</b>			514,240		523,125
<b>Creditors: amounts falling due after more than one year</b>	11		(413,415)		(430,000)
<b>Net assets</b>			100,825		93,125
<b>Reserves</b>					
Income and Expenditure account	14		100,825		93,125
<b>Members funds</b>			100,825		93,125

These financial statements were approved by the board of directors on 8th May 2024 and signed on behalf of the board by:

Elizabeth Bissett  
Director

*Elizabeth Bissett*

Thomas Crilly  
Director

*Thomas F. Crilly*

The notes on pages 11 to 20 form part of these financial statements.

**RINGSEND & DISTRICT RESPONSE TO DRUGS CLG  
(COMPANY LIMITED BY GUARANTEE)**

**STATEMENT OF CHANGES IN RESERVES  
YEAR ENDED 31ST DECEMBER 2023**

	Income and Expenditure account €	Total  €
<b>At 1st January 2022</b>	74,992	74,992
Surplus for the year	18,133	18,133
<b>Total comprehensive results for the year</b>	18,133	18,133
<b>At 31st December 2022</b>	93,125	93,125
Surplus for the year	7,700	7,700
<b>Total comprehensive results for the year</b>	7,700	7,700
<b>At 31st December 2023</b>	100,825	100,825

**RINGSEND & DISTRICT RESPONSE TO DRUGS CLG  
(COMPANY LIMITED BY GUARANTEE)**

**STATEMENT OF CASH FLOWS  
YEAR ENDED 31ST DECEMBER 2023**

	<b>2023</b>	<b>2022</b>
	<b>€</b>	<b>€</b>
<b>Cash flows from operating activities</b>		
Surplus for the financial year	7,700	18,133
<i>Adjustments for:</i>		
Depreciation of tangible assets	15,485	15,487
Accrued expenses/(income)	(16,205)	4,336
<i>Changes in:</i>		
Trade and other debtors	546	(2,352)
Trade and other creditors	(4,491)	(17,868)
Cash generated from operations	<u>3,035</u>	<u>17,736</u>
Net cash from operating activities	<u>3,035</u>	<u>17,736</u>
<b>Cash flows from investing activities</b>		
Purchase of tangible assets	-	(5,502)
Net cash from/(used in) investing activities	-	<u>(5,502)</u>
<b>Net increase/(decrease) in cash and cash equivalents</b>	<b>3,035</b>	<b>12,234</b>
<b>Cash and cash equivalents at beginning of year</b>	<b>190,153</b>	<b>177,919</b>
<b>Cash and cash equivalents at end of year</b>	<b><u>193,188</u></b>	<b><u>190,153</u></b>

**RINGSEND & DISTRICT RESPONSE TO DRUGS CLG  
(COMPANY LIMITED BY GUARANTEE)**

**NOTES TO THE FINANCIAL STATEMENTS  
YEAR ENDED 31ST DECEMBER 2023**

**1. Statement of compliance**

These financial statements have been prepared in compliance with FRS 102, 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.

**2. Accounting policies**

**Basis of preparation**

The financial statements have been prepared on the historical cost basis, as modified by the revaluation of certain financial assets and liabilities and investment properties measured at fair value through profit or loss.

The financial statements have been prepared in accordance with FRS 102 and with Irish law comprising of the Companies Act 2014.

The financial statements are prepared in Euros, which is the functional currency of the entity.

**Income**

Income is accounted for when amounts receivable on grants and funding applications are paid.

**Voluntary Income:** Voluntary income is recognised in the period in which the organisation is entitled to the resource, receipt is virtually certain and when the amount can be measured with sufficient reliability.

**Restricted Income:** Income received by the organisation, the application of which is restricted to a specific purpose by the donor, is treated as restricted income and any unspent amounts as restricted assets. Such specified purposes are within the overall aims of the organisation.

**Unrestricted Income:** Other income, apart from restricted income, is used by the organisation in the furtherance of its work and objectives. Such funds may be held in order to finance working capital or may be used at the discretion of the organisation for specified purposes that are within the aims of the organisation.

**RINGSEND & DISTRICT RESPONSE TO DRUGS CLG  
(COMPANY LIMITED BY GUARANTEE)**

**NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)  
YEAR ENDED 31ST DECEMBER 2023**

**Taxation**

The taxation expense represents the aggregate amount of current and deferred tax recognised in the reporting period. Tax is recognised in the statement of comprehensive income, except to the extent that it relates to items recognised in other comprehensive income or directly in capital and reserves. In this case, tax is recognised in other comprehensive income or directly in capital and reserves, respectively.

Current tax is recognised on taxable profit for the current and past periods. Current tax is measured at the amounts of tax expected to pay or recover using the tax rates and laws that have been enacted or substantively enacted at the reporting date.

Deferred tax is recognised in respect of all timing differences at the reporting date. Unrelieved tax losses and other deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date that are expected to apply to the reversal of the timing difference.

**Tangible assets**

Tangible assets are initially recorded at cost, and are subsequently stated at cost less any accumulated depreciation and impairment losses.

Any tangible assets carried at revalued amounts are recorded at the fair value at the date of revaluation less any subsequent accumulated depreciation and subsequent accumulated impairment losses.

An increase in the carrying amount of an asset as a result of a revaluation, is recognised in other comprehensive income and accumulated in capital and reserves, except to the extent it reverses a revaluation decrease of the same asset previously recognised in profit or loss. A decrease in the carrying amount of an asset as a result of revaluation is recognised in other comprehensive income to the extent of any previously recognised revaluation increase accumulated in capital and reserves in respect of that asset. Where a revaluation decrease exceeds the accumulated revaluation gains accumulated in capital and reserves in respect of that asset, the excess shall be recognised in profit or loss.

**Depreciation**

Depreciation is calculated so as to write off the cost or valuation of an asset, less its residual value, over the useful economic life of that asset as follows:

Freehold Property	- 2%	straight line
Computer Equipment	- 20%	straight line
Fittings fixtures and equipment	- 20%	straight line
Motor vehicles	- 20%	straight line

If there is an indication that there has been a significant change in depreciation rate, useful life or residual value of tangible assets, the depreciation is revised prospectively to reflect the new estimates.

**RINGSEND & DISTRICT RESPONSE TO DRUGS CLG  
(COMPANY LIMITED BY GUARANTEE)**

**NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)  
YEAR ENDED 31ST DECEMBER 2023**

**Impairment**

A review for indicators of impairment is carried out at each reporting date, with the recoverable amount being estimated where such indicators exist. Where the carrying value exceeds the recoverable amount, the asset is impaired accordingly. Prior impairments are also reviewed for possible reversal at each reporting date.

When it is not possible to estimate the recoverable amount of an individual asset, an estimate is made of the recoverable amount of the cash-generating unit to which the asset belongs. The cash-generating unit is the smallest identifiable group of assets that includes the asset and generates cash inflows that are largely independent of the cash inflows from other assets or groups of assets.

**Government grants**

Government grants are recognised at the fair value of the asset received or receivable. Grants are not recognised until there is reasonable assurance that the company will comply with the conditions attaching to them and the grants will be received.

Government grants are recognised using the accrual model and the performance model.

Under the accrual model, government grants relating to revenue are recognised on a systematic basis over the periods in which the company recognises the related costs for which the grant is intended to compensate. Grants that are receivable as compensation for expenses or losses already incurred or for the purpose of giving immediate financial support to the entity with no future related costs are recognised in income in the period in which it becomes receivable.

Grants relating to assets are recognised in income on a systematic basis over the expected useful life of the asset. Where part of a grant relating to an asset is deferred, it is recognised as deferred income and not deducted from the carrying amount of the asset.

Under the performance model, where the grant does not impose specified future performance-related conditions on the recipient, it is recognised in income when the grant proceeds are received or receivable. Where the grant does impose specified future performance-related conditions on the recipient, it is recognised in income only when the performance-related conditions have been met. Where grants received are prior to satisfying the revenue recognition criteria, they are recognised as a liability.



**RINGSEND & DISTRICT RESPONSE TO DRUGS CLG  
(COMPANY LIMITED BY GUARANTEE)**

**NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)  
YEAR ENDED 31ST DECEMBER 2023**

**Financial Instruments**

A financial asset or a financial liability is recognised only when the company becomes a party to the contractual provisions of the instrument.

Basic financial instruments are initially recognised at the transaction price, unless the arrangement constitutes a financing transaction, where it is recognised at the present value of the future payments discounted at a market rate of interest for a similar debt instrument.

Debt instruments are subsequently measured at amortised cost.

Where investments in non-convertible preference shares and non-puttable ordinary shares or preference shares are publicly traded or their fair value can otherwise be measured reliably, the investment is subsequently measured at fair value with changes in fair value recognised in income or expenditure. All other such investments are subsequently measured at cost less impairment.

Other financial instruments, including derivatives, are initially recognised at fair value, unless payment for an asset is deferred beyond normal business terms or financed at a rate of interest that is not a market rate, in which case the asset is measured at the present value of the future payments discounted at a market rate of interest for a similar debt instrument.

Other financial instruments are subsequently measured at fair value, with any changes recognised in profit or loss, with the exception of hedging instruments in a designated hedging relationship.

Financial assets that are measured at cost or amortised cost are reviewed for objective evidence of impairment at the end of each reporting date. If there is objective evidence of impairment, an impairment loss is recognised in profit or loss immediately.

For all equity instruments regardless of significance, and other financial assets that are individually significant, these are assessed individually for impairment. Other financial assets are either assessed individually or grouped on the basis of similar credit risk characteristics.

Any reversals of impairment are recognised in profit or loss immediately, to the extent that the reversal does not result in a carrying amount of the financial asset that exceeds what the carrying amount would have been had the impairment not previously been recognised.

**RINGSEND & DISTRICT RESPONSE TO DRUGS CLG  
(COMPANY LIMITED BY GUARANTEE)**

**NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)  
YEAR ENDED 31ST DECEMBER 2023**

**3. Critical Judgements and Estimates**

The preparation of these financial statements requires management to make judgements, estimates and assumptions that affect the application of policies and reported amounts of assets and liabilities, income and expenditure.

Judgements and estimates are continually evaluated and are based on historical experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances.

The company makes estimates and assumptions concerning the future. The resulting accounting estimates will, by definition, seldom equal the related actual results. The estimates and assumptions that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year are discussed below.

**(a) Establishing useful economic life for depreciation purpose**

The annual depreciation charge depends primarily on the estimated useful economic lives of each type of asset and estimate of residual value. The directors regularly review these assets useful lives in light of prospective economic utilisation and physical condition of the assets concerned. Changes in asset useful lives can have a significant impact on depreciation and amortisation charges for the period. Detail of the useful economic lives is included in the accounting policies.

**(b) Going concern**

The directors have prepared budgets for the next financial year which demonstrate that there is no material uncertainty regarding the company's ability to meet its liabilities as they fall due, and to continue as a going concern. On this basis the directors consider it appropriate to prepare the financial statements on a going concern basis. Accordingly, these financial statements do not include any adjustments to the carrying amounts and classification of assets and liabilities that may arise if the company were unable to continue as a going concern.

**RINGSEND & DISTRICT RESPONSE TO DRUGS CLG  
(COMPANY LIMITED BY GUARANTEE)**

**NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)  
YEAR ENDED 31ST DECEMBER 2023**

**4. Grant Income**

A. Agency Health Services Executive - South Western Health Board - Section 39

Government Department Department of Health  
Purpose of the Grant Funding the costs of running Ringsend & District Response to Drugs CLG

Accounting for Grants

- Grants Deferred as at 1st January 2023	Nil
- Grants Received during the year	278,130
- Grants taken to income in the year	278,130
- Grants Deferred as at 31st December 2023	Nil

B. Agency DSP

Government Department Department of Social Protection

Purpose of the Grant Funding the costs of running Ringsend & District Response to Drugs CE Scheme

Accounting for Grants

- Grants Deferred as at 1st January 2023	96,659
- Grants Received during the year	702,109
- Grants taken to income in the year	684,807
- Grants Deferred as at 31st December 2023	113,961

C. Agency Health Services Executive

Government Department Local Drugs & Alcohol Task Force

Purpose of the Grant Funding the costs of running Ringsend & District Response to Drugs CLG

Accounting for Grants

- Grants Deferred as at 1st January 2023	Nil
- Grants Received during the year	139,030
- Grants taken to income in the year	139,030
- Grants Deferred as at 31st December 2023	Nil

**5. Limited by guarantee**

The liability of the members is limited. In the event of the Company being wound up each member undertakes to contribute towards the payment of any debts and liabilities of the Company. Any such contribution by each member is limited to €1.27.

**RINGSEND & DISTRICT RESPONSE TO DRUGS CLG  
(COMPANY LIMITED BY GUARANTEE)**

**NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)  
YEAR ENDED 31ST DECEMBER 2023**

**6. Surplus**

Surplus is stated after charging/(crediting):

	2023	2022
	€	€
Depreciation of tangible assets	15,485	15,487
	<u>          </u>	<u>          </u>

**7. Staff costs**

The average number of persons employed by the company during the year was as follows:

	2023	2022
	Number	Number
Participants	35	38
Supervisors	4	4
Administration	2	2
Key-Working	7	7
Holistics	1	1
	<u>          </u>	<u>          </u>
	49	52
	<u>          </u>	<u>          </u>

The aggregate payroll costs incurred during the year were:

	2023	2022
	€	€
Wages and salaries	971,890	958,182
Social insurance costs	44,251	42,864
	<u>          </u>	<u>          </u>
	1,016,141	1,001,046
	<u>          </u>	<u>          </u>

No employee received employee benefits including employer pension costs of more than €60,000.

**RINGSEND & DISTRICT RESPONSE TO DRUGS CLG  
(COMPANY LIMITED BY GUARANTEE)**

**NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)  
YEAR ENDED 31ST DECEMBER 2023**

<b>8. Tangible assets</b>	<b>Freehold property</b>	<b>Computer Equipment</b>	<b>Fixtures, fittings and equipment</b>	<b>Motor vehicles</b>	<b>Total</b>
	€	€	€	€	€
<b>Cost</b>					
At 1st January 2023	683,832	55,811	86,697	72,707	899,047
Additions	-	-	-	-	-
<b>At 31st December 2023</b>	<u>683,832</u>	<u>55,811</u>	<u>86,697</u>	<u>72,707</u>	<u>899,047</u>
<b>Depreciation</b>					
At 1st January 2023	241,260	49,599	86,697	72,707	450,263
Charge for the year	13,677	1,808	-	-	15,485
<b>At 31st December 2023</b>	<u>254,937</u>	<u>51,407</u>	<u>86,697</u>	<u>72,707</u>	<u>465,748</u>
<b>Carrying amount</b>					
<b>At 31st December 2023</b>	<u>428,895</u>	<u>4,404</u>	<u>-</u>	<u>-</u>	<u>433,299</u>
<b>9. Debtors</b>				<b>2023</b>	<b>2022</b>
				€	€
Other debtors				2,012	2,866
Prepayments and accrued income				37,716	24,821
				<u>39,728</u>	<u>27,687</u>
<b>10. Creditors: amounts falling due within one year</b>				<b>2023</b>	<b>2022</b>
				€	€
Tax and social insurance:					
PAYE and social welfare				10,477	16,785
Accruals				12,053	15,671
Government grants				15,484	14,384
DEASP payment on account				113,961	96,659
				<u>151,975</u>	<u>143,499</u>

**RINGSEND & DISTRICT RESPONSE TO DRUGS CLG  
(COMPANY LIMITED BY GUARANTEE)**

**NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)  
YEAR ENDED 31ST DECEMBER 2023**

<b>11. Creditors: amounts falling due after more than one year</b>	<b>2023</b>	<b>2022</b>
	€	€
Government grants	413,415	430,000
	<u>          </u>	<u>          </u>
<b>12. Government grants</b>	<b>2023</b>	<b>2022</b>
	€	€
As at the start of the year	444,384	458,768
Released to the profit or loss	(15,485)	(14,384)
As at the end of the year	<u>428,899</u>	<u>444,384</u>
The amounts recognised in the financial statements for government grants are as follows:	<b>2023</b>	<b>2022</b>
	€	€
Recognised in creditors:		
Deferred government grants due within one year	15,484	14,384
Deferred government grants due after more than one year	413,415	430,000
	<u>428,899</u>	<u>444,384</u>
<b>13. Financial instruments</b>		
The carrying amount for each category of financial instruments is as follows:	<b>2023</b>	<b>2022</b>
	€	€
<b>Financial assets that are debt instruments measured at amortised cost</b>		
Other debtors	2,012	2,866
Cash at bank and in hand	193,188	190,153
Prepayments and accrued income	37,716	24,821
	<u>232,916</u>	<u>217,840</u>
<b>Financial liabilities measured at amortised cost</b>		
Other creditors	(10,477)	(16,785)
Accruals and deferred income	(141,498)	(126,714)
	<u>(151,975)</u>	<u>(143,499)</u>

**RINGSEND & DISTRICT RESPONSE TO DRUGS CLG  
(COMPANY LIMITED BY GUARANTEE)**

**NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)  
YEAR ENDED 31ST DECEMBER 2023**

**14. Reserves**

At the year end the company had reserves in the amount of €100,825. The reserves represent unrestricted monies available to the organisation. Section 39 and LDTF reserves at the year end were 0. DEASP reserves at the year end were 0. It is the policy of Ringsend & District Response to Drugs CLG that €90,000 is set aside for force majeure shortfalls due to potential under-funding. This balance is included in the €100,825.

**15. Ethical standard - provisions available for small entities**

In common with many other businesses of our size and nature we use our auditors to prepare and submit returns to the tax authorities and assist with the preparation of the financial statements. We also use our auditors to provide tax advice and to represent us, as necessary, at tax tribunals.

**16. Controlling party**

The controlling party of the company is their directors.

**17. Approval of financial statements**

The board of directors approved these financial statements for issue on 8 May 2024.

